YasuhiroOkiMD

PubMed

• 15 citations
  Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
  Jason Westin, R Eric Davis, Lei Feng, Fredrick Hagemeister, Raphael Steiner, Hun Ju Lee, Luis Fayad, Loretta Nastoupil, Sairah Ahmed, Alma Rodriguez, Michelle Fanale, ...> ;Journal of Clinical Oncology. 2023 Feb 1
• 5 citations
  A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.
  Hua-Jay J Cherng, Stefan K Alig, Yasuhiro Oki, Loretta J Nastoupil, Luis Fayad, Sattva S Neelapu, Francesco Turturro, Fredrick Hagemeister, Alexander F M Craig, Charle...> ;Blood Advances. 2023 Apr 11
• 15 citations
  Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker a...
  Daniel J. Landsburg, Stefan K. Barta, Radhakrishnan Ramchandren, Connie Lee Batlevi, Swaminathan P. Iyer, Kevin R. Kelly, Ivana N. Micallef, Sonali M. Smith, Don A. St...> ;British Journal of Haematology. 2021 Aug 2
• 10 citations
  Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study
  Won Seog Kim, Yasuhiro Oki, Seok Jin Kim, Sang Eun Yoon, Kirit M. Ardeshna, Yi Lin, Jia Ruan, Pierluigi Porcu, Jonathan E. Brammer, Eric D. Jacobsen, Dok Hyun Yoon, Ch...> ;Annals of Hematology. 2021 Jul 24
• 18 citations
  Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.
  Andrew M. Evens, Joseph M. Connors, Anas Younes, Stephen M. Ansell, Won Seog Kim, John Radford, Tatyana Feldman, Joseph Tuscano, Kerry J. Savage, Yasuhiro Oki, Andrew ...> ;Haematologica. 2021 Jun 24
• 27 citations
  Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral ...
  Patrick B. Johnston, Amanda F. Cashen, Petros Nikolinakos, Anne W. Beaven, Stefan K. Barta, Gajanan Bhat, Steven J. Hasal, Sven de Vos, Yasuhiro Oki, Changchun Deng, F...> ;Experimental Hematology & Oncology. 2021 Feb 18
• 3 citations
  Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
  Michael Schaffer, Shalini Chaturvedi, Cuc Davis, Jan de Jong, Regina Aquino, Yasuhiro Oki, Nele Fourneau, Anas Younes, Sriram Balasubramanian> ;Cancer Treatment and Research Communications. 2020 Nov 1
• 14 citations
  Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
  Filip Janku, Haeseong Park, S. Greg Call, Kiran Madwani, Yasuhiro Oki, Vivek Subbiah, David S. Hong, Aung Naing, Vivianne Velez-Bravo, Tamara G. Barnes, Fredrick B. Ha...> ;Clinical Cancer Research. 2020 Nov 1
• 42 citations
  Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
  Auris Huen, Bradley M. Haverkos, Jasmine Zain, Ramchandren Radhakrishnan, Mary Jo Lechowicz, Sumana Devata, Neil J. Korman, Lauren C. Pinter-Brown, Yasuhiro Oki, Praja...> ;Cancers. 2020 Aug 15
• 5 citations
  De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era.
  Bei Hu, Loretta J. Nastoupil, Sanam Loghavi, Jason R. Westin, Beenu Thakral, Luis Fayad, Fredrick B. Hagemeister, Sattva S. Neelapu, Felipe Samaniego, Hun J. Lee, Mich...> ;Leukemia & Lymphoma. 2020 Jan 28
• 17 citations
  A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas
  Paolo Strati, Loretta J. Nastoupil, Richard E. Davis, Luis Fayad, Nathan Fowler, Fredrick B. Hagemeister, Larry W. Kwak, Yasuhiro Oki, Michael Wang, Jason R. Westin, C...> ;Haematologica. 2020 Jan 1
• 34 citations
  Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial.
  Melody R. Becnel, Loretta J. Nastoupil, Felipe Samaniego, Richard E. Davis, M. J. You, Michael R. Green, Fredrick B. Hagemeister, Michelle A. Fanale, Luis Fayad, Jason...> ;British Journal of Haematology. 2019 Jun 1
• 81 citations
  Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.
  Stefan K. Barta, Jasmine Zain, Alexander W. MacFarlane, Sonali M. Smith, Jia Ruan, Henry C. Fung, Carlyn Rose C. Tan, Yibin Yang, R. Katherine Alpaugh, Essel Dulaimi, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2019 Jun 1
• 6 citations
  Erratum to: Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma: Low-dose radiotherapy for adnexal b-cell lymphoma (Head & Neck, (2...
  Chelsea C. Pinnix, Bouthaina S. Dabaja, Sarah A. Milgrom, Grace L. Smith, Zeinab Abou Yehia, Loretta J. Nastoupil, Jorge E. Romaguera, Francesco Turturro, Nathan Fowle...> ;Head & Neck. 2019 May 1
• 8 citations
  Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement.
  Dai Chihara, Yasuhiro Oki, Michelle A. Fanale, Jason R. Westin, Loretta J. Nastoupil, Sattva S. Neelapu, Luis Fayad, Nathan Fowler, Chan Yoon Cheah> ;British Journal of Haematology. 2019 Apr 1
• 47 citations
  A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma.
  Sarah A. Milgrom, Hesham Elhalawani, Joonsang Lee, Qianghu Wang, Abdallah S.R. Mohamed, Bouthaina S. Dabaja, Chelsea C. Pinnix, Jillian R. Gunther, Laurence E. Court, ...> ;Scientific Reports. 2019 Feb 4
• 5 citations
  Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.
  Dai Chihara, Shannon Wong, Tatyana Feldman, Michelle A. Fanale, Larysa Sanchez, Joseph M. Connors, Kerry J. Savage, Yasuhiro Oki> ;Hematological Oncology. 2019 Feb 1
• 6 citations
  Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides.
  Yi An, Wen Jiang, T.Y. Andraos, Jay Reddy, Zeinab Abou Yehia, Shane Lloyd, Madeleine Duvic, Neil M. D'Souza, Sarah A. Milgrom, Chelsea C. Pinnix, Yasuhiro Oki, Grace L...> ;Radiotherapy and Oncology. 2019 Feb 1
• 23 citations
  Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden
  Winnie S. Liang, Jo Anne Vergilio, Bodour Salhia, Helen J. Huang, Yasuhiro Oki, Ignacio Garrido-Laguna, Haeseong Park, Jason R. Westin, Funda Meric-Bernstam, David Fab...> ;The Oncologist. 2019 Feb 1
• 11 citations
  ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.
  Paolo Strati, Michelle A. Fanale, Yasuhiro Oki, Francesco Turturro, Luis Fayad, Nancy L. Bartlett, Douglas E. Gladstone, Yvette L. Kasamon, Carol S. Portlock, Wyndham ...> ;Haematologica. 2019 Feb 1
• 9 citations
  Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?
  Dai Chihara, Yasuhiro Oki, Michelle A. Fanale, Jason R. Westin, Loretta J. Nastoupil, Sattva S. Neelapu, Luis Fayad, Nathan Fowler, Chan Yoon Cheah> ;Annals of Hematology. 2019 Jan 8
• 2 citations
  NK-Cell Lymphomas.
  Dai Chihara, Yasuhiro Oki> ;Cancer Treatment and Research. 2019 Jan 1
• 24 citations
  Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.
  Ian W. Flinn, Manish Patel, Yasuhiro Oki, Steven M. Horwitz, F. Foss, Kerstin Allen, Mark W. Douglas, Howard M. Stern, Jennifer Sweeney, Jahnavi Kharidia, Patrick Kell...> ;American Journal of Hematology. 2018 Aug 31
• 1 citations
  Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement
  Garrett L Jensen, Bouthaina S. Dabaja, Chelsea C. Pinnix, Jillian R. Gunther, Auris Huen, Madeleine Duvic, Yasuhiro Oki, Michelle A. Fanale, Chitra Hosing, Sarah A. Mi...> ;Case Reports in Oncology. 2018 Sep 1
• 18 citations
  A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma
  Paolo Strati, Dai Chihara, Yasuhiro Oki, Luis Fayad, Nathan Fowler, Loretta J. Nastoupil, Jorge E. Romaguera, Felipe Samaniego, Naveen Garg, Lei Feng, Emily Wesson, Ch...> ;Haematologica. 2018 Sep 1
• Join now to see all

Journal Articles

• Rituximab with ABVD vs ABVD for Advanced Stage High-Risk Classical Hodgkin Lymphoma: A Randomized Phase II Study  
  Francesco Turturro, Luis E Fayad, Anas Younes, Michelle Fanale, Yasuhiro Oki, Hun Ju Lee, Nancy L Bartlett, Haematologica

Abstracts/Posters

• Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma...
  Yasuhiro Oki, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Tenalisib, a dual PI3K δ/γ inhibitor: Safety and efficacy results from an on-going phase I/Ib study in relapsed/refractory T-cell lymphoma. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018